Chronic-phase CML patients at the diagnosis. Samples from 19 CML patients with optimal response to TKI therapy (achievement of major molecular remission) and from 27 patients with poor response (26 evolved to blast phase during TKI therapy and 1 patient was resistant to all TKIs) were sequenced with exome and RNA sequencing. Genetic variants in cancer genes involving somatic mutations, fusions, and copy number variations were common in patients with poor response.